30 May 2023 | News
India’s first plasma manufacturing facility by a pure-play blood-plasma company
PlasmaGen Biosciences, a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, recently celebrated the official opening of the company's new manufacturing plant for blood plasma-derived protein therapeutics in Kolar, Bengaluru.
Spread across 8 acres, this state-of-the-art facility consists of multiple connected, yet independently operable blocks that support various operations of the manufacturing process. The facility will serve to significantly improve the supply-demand mix for blood-plasma derived products at affordable prices.
With the launch of this new facility, PlasmaGen is on a mission to improve the accessibility of blood-plasma derived products to patients in India and emerging countries. The manufacturing plant has an initial capacity to process 5,00,000 litres of plasma annually using a process technology that has been developed in-house over traditionally available technologies, resulting in higher yields of very high-quality products. The facility will produce multiple plasma products like albumin, immunoglobulins and coagulation factors. Additional capacity has been incorporated into the design, allowing PlasmaGen to expand its product portfolio in the future.
Looking ahead, the company will strengthen its team creating employment opportunities for more than 500 people, becoming the leading fully integrated pure-play plasma products company in the country.